Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22874783 | 0.84 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL26488832 | 0.84 | ALDH1A1 (0.37) | ALDH1A1THRATHRBMEN1KMT2A | |
| SCHEMBL4402796 | 0.82 | ALDH1A1 (0.44) | ALDH1A1THRATHRBCNR2MEN1 | |
| SCHEMBL4403162 | 0.82 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL15959432 | 0.79 | — | — | |
| SCHEMBL15978962 | 0.77 | MEN1 (0.44) | ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL13559724 | 0.76 | ALDH1A1 (0.46) | ALDH1A1CNR2 | |
| SCHEMBL22959646 | 0.75 | CYP2D6 (0.37) | ALDH1A1 | |
| SCHEMBL12251557 | 0.75 | HSD11B1 (0.44) | ALDH1A1CNR2 | |
| SCHEMBL24121007 | 0.75 | POLB (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493412-B2 | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150105376-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2015-04-16 | — | — | US | disclosed |
| US-8993557-B2 | Pyridinedione carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-31 | — | — | US | disclosed |
| US-8946430-B2 | Quinolinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140243314-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-28 | — | — | US | disclosed |
| US-20140235608-A1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140228321-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105376-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, PNLIP, LPL | ALDH1A1 440/4885THRA 4468/4885THRB 4148/4885 |
| US-20140243314-A1 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, PNLIP, LPL | ALDH1A1 440/4885THRA 4468/4885THRB 4148/4885 |
| US-20140228321-A1 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS | LIPG, PNLIP, LPL | ALDH1A1 390/4885THRA 4550/4885THRB 4156/4885 |
| US-20140235608-A1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, PNLIP, LPL | ALDH1A1 401/4885THRA 4289/4885THRB 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.